Long-term outcome of combined (percutaneous intramyocardial and intracoronary) application of autologous bone marrow mononuclear cells post myocardial infarction the 5-year MYSTAR study /

OBJECTIVE: The long-term (5-year) outcome of early (3-6 weeks after acute myocardial infarction [AMI], BM-MNC Early group) and late (3-4 months after AMI, BM-MNC Late group) combined (percutaneous intramyocardial and intracoronary) delivery of autologous bone marrow mononuclear cells (BM-MNCs) was...

Teljes leírás

Elmentve itt :
Bibliográfiai részletek
Szerzők: Gyöngyösi Mariann
Giurgea Georgiana-Aura
Syeda Bonni
Charwat Silvia
Marzluf Beatrice
Mascherbauer Julia
Jakab András
Zimba Abelina
Sárközy Márta
Pávó Noémi
Sochor Heinz
Graf Senta
Lang Irene
Maurer Gerald
Bergler-Klein Jutta
Dokumentumtípus: Cikk
Megjelent: Public Library of Science (PLoS) 2016
Sorozat:PLOS ONE 11 No. 10
doi:10.1371/journal.pone.0164908

mtmt:3174445
Online Access:http://publicatio.bibl.u-szeged.hu/11861
LEADER 03208nab a2200373 i 4500
001 publ11861
005 20191202115329.0
008 170830s2016 hu o 0|| zxx d
022 |a 1932-6203 
024 7 |a 10.1371/journal.pone.0164908  |2 doi 
024 7 |a 3174445  |2 mtmt 
040 |a SZTE Publicatio Repozitórium  |b hun 
041 |a zxx 
100 1 |a Gyöngyösi Mariann 
245 1 0 |a Long-term outcome of combined (percutaneous intramyocardial and intracoronary) application of autologous bone marrow mononuclear cells post myocardial infarction  |h [elektronikus dokumentum] :  |b the 5-year MYSTAR study /  |c  Gyöngyösi Mariann 
260 |a Public Library of Science (PLoS)  |c 2016 
300 |a Terjedelem: 17 p-Azonosító: e0164908 
490 0 |a PLOS ONE  |v 11 No. 10 
520 3 |a OBJECTIVE: The long-term (5-year) outcome of early (3-6 weeks after acute myocardial infarction [AMI], BM-MNC Early group) and late (3-4 months after AMI, BM-MNC Late group) combined (percutaneous intramyocardial and intracoronary) delivery of autologous bone marrow mononuclear cells (BM-MNCs) was evaluated in patients with ejection fractions (EF) between 30-45% post-AMI. METHODS: Major adverse cardiac and cerebrovascular events (MACCE) and hospitalization were recorded. Left (LV) and right (RV) ventricular function were measured by transthoracic echocardiography. Cardiac magnetic resonance imaging (MRI) and myocardial single photon emission computed tomography was performed in a subgroup of patients. Pre-cell therapy myocardial voltage values of treated areas (assessed by NOGA mapping) were correlated with clinical outcome. RESULTS: Five-year MACCE incidences (7.4%. vs 24.1%) and the composite of all adverse events (11.1% vs 27.6%) were not different between the Early and Late treatment groups. The significant LV-EF increase at 1-year follow-up was preserved at the 5-year control (from baseline to 5-year: 5.3%, 95% CI:0.5-10.1, and 5.7%, 95% CI:1.7-9.6, p<0.05 in the Early and Late groups, respectively), with no significant changes between 1- and 5-year follow-ups. Similarly, RVEF increased significantly from baseline to the 5-year follow-up (Early group: 5.4%, 95% CI:1.0-9.6; and Late group: 8.4%, 95% CI:4.5-12.3). Lower baseline levels of myocardial viability of the treated cardiac area (6.3+/-2.4 vs 8.2+/-3.0 mV, p<0.05) were associated with incidence of MACCE. CONCLUSIONS: Percutaneous combined delivery of autologous BM-MNCs is feasible and safe after 5 years, and may result in sustained improvement of cardiac function at 5 years in patients with low EF post-AMI (Clinicaltrials.gov NCT01395212). 
700 0 1 |a Giurgea Georgiana-Aura  |e aut 
700 0 1 |a Syeda Bonni  |e aut 
700 0 1 |a Charwat Silvia  |e aut 
700 0 1 |a Marzluf Beatrice  |e aut 
700 0 1 |a Mascherbauer Julia  |e aut 
700 0 1 |a Jakab András  |e aut 
700 0 1 |a Zimba Abelina  |e aut 
700 0 1 |a Sárközy Márta  |e aut 
700 0 1 |a Pávó Noémi  |e aut 
700 0 1 |a Sochor Heinz  |e aut 
700 0 1 |a Graf Senta  |e aut 
700 0 1 |a Lang Irene  |e aut 
700 0 1 |a Maurer Gerald  |e aut 
700 0 2 |a Bergler-Klein Jutta  |e aut 
856 4 0 |u http://publicatio.bibl.u-szeged.hu/11861/1/journal.pone.0164908.PDF  |z Dokumentum-elérés